Mechanisms controlling protein release from lipidic implants: effects of PEG addition

S Herrmann, G Winter, S Mohl, F Siepmann… - Journal of controlled …, 2007 - Elsevier
Different types of tristearin-based implants for controlled rh-interferon α-2a (IFN-α) release
were prepared by compression and thoroughly characterised in vitro. Hydroxypropyl-β-…

Continuous release of rh-interferon α-2a from triglyceride matrices

S Mohl, G Winter - Journal of controlled release, 2004 - Elsevier
The use of biodegradable polymeric matrices as controlled release systems is known to be
associated with various drawbacks. The objective of this study was to develop an alternative …

Challenges for the pharmaceutical technical development of protein coformulations

C Mueller, U Altenburger, S Mohl - Journal of Pharmacy and …, 2018 - academic.oup.com
Objectives This review discusses challenges to stability, analytics and manufacturing of
protein coformulations. Furthermore, general considerations to be taken into account for the …

New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants

S Herrmann, S Mohl, F Siepmann, J Siepmann… - Pharmaceutical …, 2007 - Springer
Purpose It has recently been shown that the addition of polyethylene glycol 6000 (PEG) to
lipidic implants fundamentally affects the resulting protein release kinetics and moreover, the …

Impact of vial capping on residual seal force and container closure integrity

…, M Vogt, H Roehl, J Huwyler, S Mohl… - PDA journal of …, 2016 - journal.pda.org
The vial capping process is a critical unit operation during drug product manufacturing, as it
could possibly generate cosmetic defects or even affect container closure integrity. Yet there …

The pharmaceutical vial capping process: container closure systems, capping equipment, regulatory framework, and seal quality tests

…, M Adler, J Huwyler, A Streubel, S Mohl - European Journal of …, 2016 - Elsevier
Parenteral drug products are protected by appropriate primary packaging to protect against
environmental factors, including potential microbial contamination during shelf life duration. …

NIR spectroscopy—a non-destructive analytical tool for protein quantification within lipid implants

T Schönbrodt, S Mohl, G Winter, G Reich - Journal of controlled release, 2006 - Elsevier
Lipid implants have been proposed as promising sustained release devices for the parenteral
application of pharmaceutical proteins. Near infrared spectroscopy (NIRS) has been …

Continuous release of rh-interferon α-2a from triglyceride implants: storage stability of the dosage forms

S Mohl, G Winter - Pharmaceutical development and technology, 2006 - Taylor & Francis
Tristearin implants containing polyethylene glycol 6000 (PEG) were shown to be a promising
platform for the delivery of pharmaceutical proteins for periods up to 1 month. The objective …

Influence of different container closure systems and capping process parameters on product quality and container closure integrity (CCI) in GMP drug product …

…, J Eder, K Fritsch, T Posset, S Mohl… - PDA journal of …, 2016 - journal.pda.org
Capping equipment used in good manufacturing practice manufacturing features different
designs and a variety of adjustable process parameters. The overall capping result is a …

Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing

…, S Kronenberg, RH Lindecrona, S Mohl… - Regulatory Toxicology …, 2018 - Elsevier
Biological drugs comprise a wide field of different modalities with respect to structure,
pharmacokinetics and pharmacological function. Considerable non-clinical experience in the …